Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV)Â +Â Chemotherapy (CT) for Ovarian Cancer (OC)
Birrer, M.J., Lankes, H., Burger, R.A., Mannel, R., Homesley, H., Henschel, V., Sovak, M., Scherer, S.J., de Haas, S., Pallaud, C.Volume:
23
Journal:
Annals of Oncology
DOI:
10.1016/s0923-7534(20)32763-0
Date:
September, 2012
File:
PDF, 78 KB
2012